7-Day vs 1-Day Packaging for Small Quantity Lipid-Based Nutrient Supplements in Ghana (SQLNS:7D-1D Comparison)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBoston University Charles River Campus

About this trial

This cluster-randomized crossover trial evaluates whether the packaging format of small-quantity lipid-based nutrient supplements (SQ-LNS) affects caregiver adherence and acceptability when SQ-LNS are delivered through routine growth monitoring services in Northern Ghana. SQ-LNS are a proven intervention for reducing child malnutrition, but packaging format may affect how caregivers store, dispense, and use the product, and it also drives cost and distribution logistics. Up to sixteen health facilities participating in growth monitoring services each deliver both formats: a 1-day sachet (20 g daily) and a 7-day resealable pouch (140 g weekly), with the order of delivery randomized at facility level. Each format is delivered for one month before crossover, and caregivers receive a 28-day supply totaling 560 g in each period regardless of format. The primary outcome is adherence, measured by weighing SQ-LNS returned unconsumed and expressed as the percentage of dispensed product consumed. The trial tests whether adherence with the 7-day pouch is non-inferior to adherence with 1-day sachets, using a margin of 5.0 percentage points. Secondary outcomes include caregiver acceptability and preference, observed dispensing accuracy and package opening, and qualitative assessment of implementation facilitators and barriers. This implementation research study uses a convergent mixed-methods design, integrating quantitative adherence and acceptability data with in-depth interviews and structured observations to inform real-world program implementation. Findings will guide policy and program decisions for integrating SQ-LNS into child health platforms in Ghana and other low-resource settings.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

The caregiver is 18 years or older and is the primary caregiver of the child

The child is 6-24 months of age at the time of enrollment

The child is eligible to receive routine growth monitoring and promotion services at the participating clinic

The caregiver provides written informed consent to participate

Disqualifiers

The child has severe acute malnutrition (SAM) or medical complications requiring medication or inpatient care

The child has a known allergy to peanuts, milk, or other components of the supplement, or has a medical condition that prevents consumption of complementary foods

The caregiver or child is concurrently enrolled in another nutrition intervention study or clinical trial

The family plans to relocate outside the study area during the two-month follow-up

Trial design

Design model

Crossover

Treatments tested in this trial

  • small-quantity lipid-based nutrient supplements (SQ-LNS)

    Dietary supplement

    Small-quantity lipid-based nutrient supplements are delivered through routine growth monitoring and promotion services in two packaging formats: 1-day 20 g sachets (20DS) and 7-day 140 g resealable pouches (7DRP). Every caregiver receives both formats, one per month, in the order determined by their facility's randomized sequence. In each period the caregiver receives a 28-day supply totaling 560 g.

Treatment groups

505 Participants
are divided into 2 treatment groups
Group A: Arm 1 (1-day sachet first)Active comparator 1 intervention
Group B: Arm 2 (7-day pouch first)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Adherence to SQ-LNS, measured as the percentage of dispensed product consumed

Weight-based adherence, calculated as 100 × (grams of SQ-LNS dispensed - grams of SQ-LNS returned unconsumed) / grams of SQ-LNS dispensed, with returned product weighed net of packaging tare. Participants in both arms receive a 28-day supply totaling 560 g per period (28 × 20 g sachets in the 1-day sachet arm; 4 × 140 g resealable pouches in the 7-day pouch arm). Returned product is weighed at the first contact point reached, following a fixed sequence: the next scheduled growth monitoring clinic visit, then a community outreach growth monitoring event, then a home visit. The 7-day resealable pouch is assessed for non-inferiority to the 1-day sachet using a non-inferiority margin of 5.0 percentage points.

Time frame
Measured twice per participant: End of each one-month packaging period (Period 1 and Period 2)

Secondary outcomes

1

Caregiver acceptability/usability

Caregiver acceptability/usability will be defined as a composite score (Likert-scaled) capturing acceptability, preference, usability, and ease of administration of the SQ-LNS packaging

Time frame
Measured twice per participant: at the end of the first 1-month phase and at the end of the second 1-month phase
2

Caregiver experience with SQ-LNS

Qualitative assessment of caregiver experience with SQ-LNS, including perceptions of packaging, feeding practices, and overall acceptability, collected through semi-structured interviews and analyzed using thematic content analysis.

Time frame
At the end of each 1-month crossover period (following each intervention phase)
3

Dispensing accuracy, measured as the percentage of caregivers dispensing a single day's dose within ±2 g of the 20 g target

At a brief facility-based observation, the caregiver opens the package and dispenses one day's dose into a tared container, which the enumerator weighs. Accuracy is recorded as whether the dispensed dose falls within ±2 g of the 20 g target.

Time frame
at the end of the first 1-month phase and at the end of the second 1-month phase
4

Percentage of caregivers opening the package without a tool or assistance

At the same facility-based observation, the enumerator records whether the caregiver opens the package without using a tool and without assistance.

Time frame
at the end of the first 1-month phase and at the end of the second 1-month phase

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Boston University Charles River Campus

Lead sponsor

University of Ghana

Collaborator

Edesia

Collaborator